Article authored by Michele D. Pierri, MD
Cardiac Surgeon & Medical Technology Researcher
Last updated: July 2026
Reading time: 5 minutes
Ten patients. Zero recurrences. That’s the headline buried inside a small New England Journal of Medicine report that, frankly, deserved more attention than it got. In April, a Johns Hopkins team used personalized “digital twins” of the heart to guide ablation in patients with ventricular tachycardia, hitting a 100% long-term success rate against a historical baseline of 60%.
It’s one data point among many. But it captures the texture of this quarter better than any market-growth chart could. Our Q1 2026 review called the prevailing mood the “Clinical Era”: AI moving from “can this work?” to “how do we deploy it?” Q2 is where that label gets tested against actual evidence, in actual procedure rooms, on actual patients.
April through June 2026 wasn’t about AI promising to transform medicine anymore. It was about specific tools, in specific procedure rooms, changing specific numbers. Sometimes dramatically. Sometimes only at the margins, and almost always with caveats attached.
Six threads stood out: a benchmarking study that embarrassed the clinical-AI regulatory pathway, cardiac digital twins moving from concept to FDA-approved trial, robotic cardiac surgery getting a serious second act, wearables earning a place in arrhythmia screening protocols, regulators on both sides of the Atlantic recalibrating timelines, and a documentation boom running ahead of the legal framework meant to govern it.
When General-Purpose Chatbots Beat the “Real” Clinical AI
Last quarter’s headline was GPT-5’s 29% jump in clinical reasoning on MedXpertQA; impressive, but an isolated benchmark number, the kind that’s easy to wave away as lab performance. On June 23, Nature Medicine published a study that makes that number much harder to dismiss. Researchers pitted general-purpose large language models (GPT-5.2, Gemini 3.1 Pro, and Claude Opus 4.6) against two FDA-pathway-adjacent specialist tools, OpenEvidence and Wolters Kluwer’s UpToDate Expert AI, using real questions submitted by practicing physicians. The chatbots won, across every benchmark tested.
Here’s the uncomfortable part: FDA’s current oversight machinery, including the December 2024 guidance on Predetermined Change Control Plans, governs how a cleared device is allowed to change after market entry. It says nothing about whether that cleared device’s baseline performance holds up against an uncleared alternative a physician can open in another browser tab. Clearance answers “does this meet its own spec.” It doesn’t answer “is this actually the best tool for the question.”
For cardiac and ICU teams leaning on AI-assisted decision support (sepsis alerts, arrhythmia triage, risk scoring), this matters beyond academic curiosity. If the validated tool underperforms the chatbot sitting on a resident’s phone, who is accountable for that gap? Nobody has a clean answer yet. The FDA’s Digital Health Center of Excellence says updated guidance on clinical decision support categorization is coming sometime in 2026. Until then, the validation gap is real, and it is currently unmonitored.
Cardiac Digital Twins Leave the Lab
If one story this quarter deserves a slow read, it’s the TWIN-VT trial. Natalia Trayanova’s group at Johns Hopkins built personalized computational replicas of the heart (derived from contrast-enhanced MRI) for ten patients with post-infarct ventricular tachycardia. Before any catheter touched real tissue, the team simulated dozens of ablation strategies on the digital twin, identifying which circuits were actually driving the arrhythmia rather than relying solely on intraprocedural mapping.
The result, published in NEJM on April 1: zero inducible arrhythmias post-ablation in all ten patients, and at more than a year of follow-up, all ten remained arrhythmia-free. Eight came off antiarrhythmic medication entirely. Compare that with the roughly 60% long-term success rate typical of conventional VT ablation, and the gap is hard to ignore.
Ten patients is not a trial that changes practice on its own; let’s be honest about that. The Hopkins team knows it too. They’re already planning a larger multicenter study, plus a parallel digital-twin trial for atrial fibrillation. Separately, a JMIR Cardio systematic review published in January catalogued how far digital twins have already spread across precision cardiology (therapy planning, arrhythmia risk prediction, heart failure modeling), while flagging that implementation barriers (computational cost, integration with EP lab workflows, regulatory pathways for “n-of-1” simulations) remain largely unsolved. The TWIN-VT result is a proof of concept with real teeth. Whether it generalizes outside a handful of academic EP labs is the question that actually matters.
Robotic Cardiac Surgery Gets a Second Act
Q1 tracked surgical robotics pushing into new anatomical territory: the Polaris platform’s first robotic cataract surgery, Medtronic’s Hugo taking its first commercial U.S. soft-tissue case. Q2’s expansion story has a different shape: a comeback, not a debut. Intuitive Surgical spent the early 2000s trying to make cardiac surgery a da Vinci use case, then largely walked away from it; first-generation hardware and a thin training infrastructure made the specialty more trouble than it was worth. That changed in January, when the FDA cleared the da Vinci 5 platform for nine cardiac procedures: mitral and tricuspid valve repair, mitral valve replacement, left atrial appendage closure, internal mammary artery mobilization, atrial septal defect repair, atrial myxoma excision, patent foramen ovale closure, and epicardial pacing lead placement.
This is not a trivial list. Valve repair and LAA closure sit at the commercial core of companies like Boston Scientific, Abbott, and Edwards Lifesciences; Intuitive is now positioned to compete on the surgical-access side of that market, not just the device side. The pitch to surgeons: smaller incisions, no sternotomy, the precision benefits of motion scaling and tremor suppression that general surgery has enjoyed for two decades.
Intuitive isn’t rushing this. The rollout plan for 2026 is deliberately narrow: a limited number of U.S. sites, paired with a dedicated cardiac training and instrumentation program. More than 140,000 robotic cardiac procedures have been performed worldwide since 2002, mostly outside the U.S., so the clinical experience base exists. What’s been missing is a coherent training pipeline, and that’s precisely what this initiative is trying to fix. Anyone who’s sat through a cardiac surgery learning curve knows how much that infrastructure piece matters, arguably more than the robot itself.
Wearables Earn a Spot in the AF Screening Pathway
Q1’s monitoring story ran through Wake Forest’s continuous post-op telemetry and AliveCor’s expanding menu of smartphone-ECG indications: general-purpose surveillance, broadly framed. Q2 narrows the lens to one specific, high-stakes question. Does a consumer wearable actually catch atrial fibrillation that would otherwise go undetected? The EQUAL trial, run across two Dutch centers and published in JACC, gave that question its most rigorous test yet, in a genuinely high-risk population. Among 437 patients aged 65 and older with elevated CHA2DS2-VASc scores, those randomized to Apple Watch-based telemonitoring saw an absolute 7.3% increase in new AF diagnoses compared with standard care, a number needed to screen of just 14.
What’s notable isn’t just the detection rate. It’s how the AF showed up: 57.1% of smartwatch-detected episodes were asymptomatic, versus zero in the control arm, where by definition every diagnosis followed a symptom. That’s the entire argument for continuous screening in one statistic. Symptom-triggered care misses a population that a wearable, worn passively, does not.
Positive predictive value came in at 54%: not great, not terrible, and a reminder that every alert still needs a human in the loop before anticoagulation starts. The trial wasn’t powered for clinical outcomes, and the investigators say so plainly. Whether earlier detection of subclinical AF actually reduces stroke or heart failure is a question for ongoing trials like REGAL and SAFER, not this one. Still, EQUAL (alongside the Heartline study reporting at ACC’s late-breaker session in March) pushes consumer wearables further into mainstream cardiology workflow than they’ve been before.
Regulators Recalibrate, on Both Sides of the Atlantic
Two regulatory threads moved in opposite directions this quarter. In the U.S., the FDA’s running tally (1,451 authorizations as of last quarter’s count) kept climbing: 24 new AI/ML clearances in March alone, 27 more in April, most still in radiology but with other specialties gaining share. Call it comfortably past 1,500 by the end of June, though the FDA’s own list updates in batches, so any single-day count is already stale by the time someone cites it. Separately, in March, RecovryAI received breakthrough device designation for a patient-facing generative AI application, a procedural first for that category. No generative AI device has yet been cleared for marketing outright, though.
In Brussels, the direction was toward relief rather than acceleration. Q1 flagged the EU’s proposed “Digital Omnibus” as a tell that nobody, regulators included, was ready for the August 2026 deadline. That proposal stopped being theoretical on May 7, when EU negotiators reached provisional agreement on the package, pushing back the compliance deadline for high-risk, use-based AI systems (Annex III, which covers most clinical decision-support software) from August 2026 to December 2027. Product-regulated systems tied to existing medical device frameworks (Annex I) move from August 2027 to August 2028.
Why the delay? Partly industry pressure, partly a recognition that conformity assessment infrastructure for AI-specific medical devices simply isn’t ready continent-wide. Whether this counts as pragmatic sequencing or a missed window to set a global standard depends on who you ask, and reasonable people disagree. What’s consistent across both jurisdictions is the same theme from the Nature Medicine benchmark study above: the rulebook describes how a cleared product should evolve, far more thoroughly than it describes how to judge whether the product should have been preferred over the alternative sitting one tab over.
Ambient Scribes Scale Up, and the Liability Question Follows
Adoption numbers for ambient AI documentation crossed a real threshold this quarter. Roughly a third of U.S. clinicians now have access to an ambient scribe, the VA is rolling deployment out nationally, and industry forecasts put access above 50% of providers by year-end. A retrospective emergency-department study found 11.2% of eligible encounters used ambient AI: modest, but climbing, with physicians favoring lower-acuity, non-interpreted visits first. Sensible caution, that.
The benefits in the literature are consistent: less documentation time, lower self-reported cognitive load, better-rated patient interactions. But (and this is where the narrative needs a second sentence, not a victory lap) current systems still produce a meaningful rate of omissions and intermittent factual inaccuracies. A scribe that drops a detail from a cardiology follow-up is a different kind of risk than a scribe that mistypes a restaurant order.
That risk is starting to show up in courtrooms, if not yet specifically tied to scribes. Medical malpractice claims involving AI are still rare, but legal analysts are already mapping where liability will land: physicians remain “ultimately responsible,” hospitals face exposure for inadequate vetting and training, and (a newer wrinkle) software vendors are seeing more product-liability claims when their tools misfire. Pennsylvania’s attorney general sued Character.AI this quarter over a companion bot misrepresenting itself as licensed medical support, the first state enforcement action of its kind. California’s AB 2013, requiring AI training-data disclosures, takes effect January 1, 2026, and several lawyers expect it to become a template elsewhere. The documentation tools are scaling faster than the case law. That gap won’t stay empty for long.
Key Takeaways
- General-purpose LLMs (GPT-5.2, Gemini 3.1 Pro, Claude Opus 4.6) outperformed FDA-cleared clinical AI tools on real physician queries in a June Nature Medicine benchmark, exposing a validation gap current regulation doesn’t address.
- Cardiac digital twins moved from concept to FDA-approved clinical trial: the TWIN-VT study (NEJM, April 2026) reported 100% long-term ablation success in 10 VT patients versus a 60% historical baseline.
- Intuitive’s da Vinci 5 received FDA clearance for nine cardiac procedures in January, marking the company’s most serious return to cardiac surgery since 2002.
- The EQUAL trial showed smartwatch-based AF screening lifted diagnosis rates by 7.3% in high-risk older adults, with the majority of detected episodes asymptomatic, though positive predictive value (54%) still demands clinical confirmation.
- The EU’s AI Act “Digital Omnibus” delays high-risk compliance deadlines for clinical AI to December 2027 (use-based) and August 2028 (device-integrated), while the FDA’s AI device count (1,451 last quarter) pushes past 1,500.
- Ambient AI documentation adoption is approaching one-third of U.S. clinicians, but persistent omission and accuracy issues are colliding with an emerging, still-undefined AI liability landscape.
Looking Ahead
Watch for three things heading into Q3. First, whether the FDA’s Digital Health Center of Excellence actually delivers the promised 2026 guidance on clinical decision-support categorization, and whether it engages with the comparative-performance question the Nature Medicine study raised, rather than sidestepping it. Second, whether Hopkins’ multicenter TWIN-VT follow-on enrolls quickly enough to generate data before the AF-focused digital-twin trial reports. Third, whether any malpractice case lands squarely on an AI documentation or decision-support tool. Because once one does, the slow-moving liability conversation of this quarter turns urgent overnight.
References
Shapiro Administration Sues Character.AI Over Fake Medical Claims – Commonwealth of Pennsylvania, 2026
Nature Medicine: General-purpose chatbots outperform clinical AI tools on physicians’ real-world questions – Nature Medicine, June 23, 2026
Chrispin J, et al. Digital Twin–Guided Ablation for Ventricular Tachycardia – New England Journal of Medicine, April 1, 2026
Digital twin hearts improve outcomes in arrhythmia ablation procedures – News-Medical / Johns Hopkins University, April 1, 2026
Technologies, Clinical Applications, and Implementation Barriers of Digital Twins in Precision Cardiology: Systematic Review – JMIR Cardio, January 2026
Intuitive’s cardiac initiative includes valve repair, LAA closure – MedTech Dive, January 26, 2026
Robotic cardiac surgery building momentum thanks to RAVR, other breakthroughs – Cardiovascular Business, 2026
Smartwatch Increases AF Diagnosis in Older, High-risk Patients: EQUAL – TCTMD, January 23, 2026 (updated March 2026)
EU AI Act Update: Timeline Relief, Targeted Simplification, and New Prohibitions – Global Policy Watch, May 28, 2026
FDA AI/ML SaMD Guidance: Complete 2026 Compliance Guide – IntuitionLabs, 2026 (industry analysis, flagged as secondary source; cross-check against FDA’s official AI-Enabled Medical Devices list)
FDA: Artificial Intelligence-Enabled Medical Devices List – U.S. FDA (primary source)
FDA Updates AI List with New Clearances – The Imaging Wire, March 11, 2026 (monthly clearance pace cited for the Q2 running-total estimate; cross-check against the FDA list directly)
Ambient Artificial Intelligence Scribe Adoption and Documentation Time in the Emergency Department – Annals of Emergency Medicine, 2026
Barriers and opportunities of scaling ambient AI scribes for clinical documentation across diverse healthcare settings – npj Digital Medicine, 2026
The new malpractice frontier: Who’s liable when AI gets it wrong? – Medical Economics, 2026 (commentary piece, useful for context, not a primary legal source)